• 

  August 18, 2026

  Pluristyx Is Building the Manufacturing Layer Behind Biofabricated Liver Therapies

  Ricky Solorzano

• 

  July 19, 2026

  Vivodyne Is Trying to Industrialize Human Tissue Testing

  Ricky Solorzano

• 

  July 13, 2026

  STEMCELL Technologies and CCRM Build a Matched iPSC Path from Research to GMP

  Ricky Solorzano

• 

  July 2, 2026

  TREGZI and the Business of Precision-Built Cell Therapies

  Ricky Solorzano

• 

  May 14, 2026

  Why Hypoparathyroidism May Be the Best First Market for Biofabricated Endocrine Tissue Therapeutics

  Ricky Solorzano

• 

  May 1, 2026

  XellSmart Launches Phase II Trial of Off-the-Shelf iPSC Cell Therapy for Parkinson’s

  Ricky Solorzano

• 

  April 30, 2026

  Eli Lilly Pays Up to $7B for Kelonia’s In Vivo CAR-T Platform and What It Means for Cell Therapy Manufacturing

  Ricky Solorzano

• 

  April 27, 2026

  The Organ-on-Chip, Microphysiological Systems Landscape, NAMs: A Business Overview

  Ricky Solorzano

• 

  April 24, 2026

  Linton Lifesciences Launches Biofabricated NAMs: Rebuilding the Missing Layer Between Biology and Decision-Making

  Ricky Solorzano

• 

  March 3, 2026

  Cellares Raises $257M to Industrialize Cell Therapy Manufacturing

  Ricky Solorzano